Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia

被引:57
作者
Lloyd-Smith, E
Brodkin, E
Wood, E
Kerr, T
Tyndall, MW
Montaner, JSG
Hogg, RS
机构
[1] Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V6T 1W5, Canada
[2] Univ British Columbia, Community Med Program, Vancouver, BC V6T 1W5, Canada
[3] Univ British Columbia, Dept Med, Vancouver, BC V6T 1W5, Canada
[4] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada
关键词
life expectancy; HIV-positive; injection drug use; HAART; potential years of life lost;
D O I
10.1097/01.aids.0000206508.32030.92
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The introduction of HAART has led to consistent improvements in survival among HIV-infected individuals. However, there is evidence that not all populations have benefited equally from HAART and that mortality rates are higher in HIV-infected injection drug users than in non-users. Objective: To model life expectancies for HIV-positive individuals subdivided according to history of injection drug use and treatment with HAART. Design: Population-based study of HIV-positive persons in British Columbia's HIV/ AIDS treatment program. Methods: The primary outcome measures in this study were life expectancy at exact age 20 and potential years of life lost. Results: The highest life expectancy (38.9 years) and lowest potential years of life lost were measured for individuals taking HAART and without a history of injection drug use. The lowest life expectancy (19.1 years) and highest potential years of life lost were measured in HIV-positive injection drug users who were not taking HAART. Conclusions: There are substantial disparities in life expectancy for persons living With HIV in British Columbia. Members of the injection drug community, particularly those who are not taking HAART, experience elevated mortality in comparison with those without a history of drug use. (C) 2006 Lippincott Williams & Wilkins.
引用
收藏
页码:445 / 450
页数:6
相关论文
共 32 条
  • [1] Babiker A, 2000, LANCET, V355, P1131, DOI 10.1016/S0140-6736(00)02061-4
  • [2] *BC STATS, 2005, BC STATS POP SECT
  • [3] Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients
    Braitstein, P
    Yip, B
    Montessori, V
    Moore, D
    Montaner, JSG
    Hogg, RS
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 173 (02) : 160 - 164
  • [4] BURR K, 1995, MORTALITY HLTH STATU
  • [5] *CHASE PROJ TEAM, 2005, COMM HLTH SAF EV CHA
  • [6] Cinti S K, 2000, AIDS Read, V10, P709
  • [7] CRAIB KJ, 2002, 11 CAN ASS HIV RES C
  • [8] Social health inequalities during the course of chronic HIV disease in the era of highly active antiretroviral therapy
    Dray-Spira, R
    Lert, F
    [J]. AIDS, 2003, 17 (03) : 283 - 290
  • [9] Access to health care and geographic mobility of HIV/AIDS patients
    Hogg, RS
    Schechter, MT
    Schilder, A
    Le, R
    Strathdee, SA
    Goldstone, IL
    OShaughnessy, MV
    [J]. AIDS PATIENT CARE, 1995, 9 (06): : 297 - 302
  • [10] HOGG RS, 1994, CAN MED ASSOC J, V150, P711